ARGENX US, INC.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$32.2M
Doctors Paid
8,326
Transactions
51,709
2024 Total
$14.0M
Payment Breakdown by Category
Research$23.2M (71.8%)
Consulting$4.2M (13.0%)
Food & Beverage$1.1M (3.5%)
Travel$768,052 (2.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $23.2M | 7,427 | 71.8% |
| Consulting Fee | $4.2M | 1,055 | 13.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.7M | 1,027 | 8.5% |
| Food and Beverage | $1.1M | 39,749 | 3.5% |
| Travel and Lodging | $768,052 | 2,220 | 2.4% |
| Space rental or facility fees (teaching hospital only) | $148,300 | 35 | 0.5% |
| Grant | $105,000 | 6 | 0.3% |
| Education | $6,567 | 189 | 0.0% |
| Charitable Contribution | $5,000 | 1 | 0.0% |
Payments by Type
Research
$23.2M
7,427 transactions
General
$9.1M
44,282 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and the Safety of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia | $1.7M | 0 | 737 |
| Quincy Model - A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with postCOVID-19 postural orthostatic tachycardia syndrome (POTS) | $1.4M | 0 | 1,163 |
| Quincy Model - Open-Label Extension Study to Evaluate the Long term Safety and Efficacy of Efgartigimod in Adult Patients with Post-COVID-19 Postural Orthostatic Tachycardia Syndrome (PC-POTS) who Completed Study ARGX 113-2104 | $1.4M | 0 | 669 |
| A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | $1.4M | 4 | 795 |
| Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS | $1.3M | 0 | 402 |
| A Long-term, Single-Arm, Open-label, Multicenter Phase 3 Study to Evaluate the Safety and Tolerability of Multiple Subcutaneous Injections of Efgartigimod PH20 SC in Patients With Generalized Myasthenia Gravis | $1.2M | 0 | 153 |
| A Long-Term, Single-Arm, Open-label, Multicenter Phase 3 Study to Evaluate the Safety and Tolerability of Multiple Subcutaneous Injections of Efgartigimod PH20 SC in Patients With Generalized Myasthenia Gravis | $1.1M | 0 | 154 |
| Safety and Efficacy of Efgartigimod in Guillain-Barre Syndrome | $1.0M | 0 | 4 |
| A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Subcutaneously Administered Efgartigimod with rHuPH20 in Adult Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | $985,381 | 0 | 312 |
| Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | $875,184 | 0 | 290 |
| A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy | $766,106 | 0 | 87 |
| Argenx LRP4 Receptor Project | $673,739 | 0 | 2 |
| A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older with Acve Idiopathic Inflammatory Myopathy | $623,173 | 2 | 331 |
| A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | $571,034 | 0 | 178 |
| A Randomized, Double-Blinded, Placebo-Controlled Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Pemphigus (Vulgaris or Foliaceus) | $478,079 | 0 | 104 |
| A Phase 3b, Randomized, Open-label, Parallel-Group Study to Evaluate Different Dosing Regimens of Intravenous Efgartigimod to Maximize and Maintain Clinical Benefit in Patients With Generalized Myasthenia Gravis (gMG) | $457,805 | 0 | 100 |
| An Open-Label, Multicenter, Follow-up Trial of ARGX-113-1904 to Evaluate the Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients with Pemphigus | $445,393 | 0 | 93 |
| A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid | $432,282 | 0 | 96 |
| A Long-Term, Single Arm, Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety and Tolerability of Multiple Subcutaneous Injections of Efgartigimod PH20 SC in Patients With Generalized Myasthenia Gravis. | $411,046 | 0 | 102 |
| A Long-Term, Single-Arm, Open-Label, Multicenter, Phase 3 Follow-on Trial of ARGX-113-1704 to Evaluate the Safety and Tolerability of ARGX-113 in Patients With Myasthenia Gravis Having Generalized Muscle Weakness | $375,110 | 0 | 45 |
| Estimating the Burden of Autoimmune Diseases in the U.S. | $375,000 | 0 | 3 |
| TREATMENT OF MYASTHENIA GRAVIS EXACERBATION OR CRISIS WITH EFGARTIGIMOD A SINGLE ARM, OPEN LABEL PROSPECTIVE COHORT STUDY | $352,310 | 0 | 2 |
| Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Subcutaneously Administered Efgartigimod with rHuPH20 in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | $318,874 | 0 | 120 |
| A Phase 3, Multicenter, Open-label, Long-term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX 113) 10 mg/kg Intravenous in Adult Patients With Primary Immune Thrombocytopenia | $291,283 | 0 | 85 |
| A Phase 3b, Randomized, Open-label, Parallel-Group Study to Evaluate Different Dosing Regimens of Intravenous Efgartigimod to Maximize and Maintain Clinical Benefit in Patients With Generalized Myasthenia Gravis | $287,113 | 0 | 97 |
| A Phase 2/3, Randomized, Double-Blinded, Placebo Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid | $285,420 | 0 | 86 |
| A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC administered by prefilled syringe (PFS) in Adult Participants with active Thyroid Eye Disease | $252,579 | 2 | 517 |
| A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). | $242,703 | 0 | 48 |
| An Open-Label, Multicenter, Follow-up Trial of ARGX-113-1904 to Evaluate the Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Pemphigus | $228,799 | 0 | 49 |
| An Open-Label, Multicenter, Follow-up Trial of ARGX-113-1904 to Evaluate the Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Pemphigus (ADDRESS+) | $220,079 | 0 | 74 |
Payments by Medical Specialty
Top Paid Doctors — Page 3
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Karissa Gable, Md, MD | Internal Medicine | Durham, NC | $29,676 | $0 |
| Dr. Jennifer Buczyner, M.d, M.D | Neurology | Jupiter, FL | $29,080 | $0 |
| Dr. Melanie Taylor, M.d, M.D | Neurology | Grand Rapids, MI | $29,035 | $0 |
| Dr. Ravindra Sarode, Md, MD | Blood Banking & Transfusion Medicine | Dallas, TX | $28,487 | $0 |
| Dr. Brian Droker, Md, MD | Neurology | Carlsbad, CA | $27,524 | $0 |
| Beth Stein, Md, MD | Neurology | Paterson, NJ | $27,369 | $0 |
| Dr. Catherine Broome, Md, MD | Hematology & Oncology | Washington, DC | $26,762 | $0 |
| Dr. Frederic Nguyen, M.d, M.D | Neurology | Richardson, TX | $26,237 | $0 |
| Ms. Jerrica Farias | Nurse Practitioner | Tampa, FL | $25,660 | $0 |
| Dr. Amit Sachdev, M.d., Ms, M.D., MS | Neurology | East Lansing, MI | $25,637 | $0 |
| Robert Sergott, Md, MD | Ophthalmology | Philadelphia, PA | $24,972 | $0 |
| Sami Khella, Md, MD | Neurology | Philadelphia, PA | $24,966 | $0 |
| Dr. Steven Evans, M.d, M.D | Anesthesiology | Las Vegas, NV | $23,760 | $0 |
| Dr. Andrew Lerman, M.d, M.D | Neurology | Miami, FL | $22,456 | $0 |
| Donna Culton, Md, MD | Dermatology | Chapel Hill, NC | $22,287 | $0 |
| Dr. Stanley Jordan, Md, MD | Internal Medicine | West Hollywood, CA | $22,200 | $0 |
| Dr. Michael Hehir, Md, MD | Neurology | Burlington, VT | $22,109 | $0 |
| Alyson Hommel, Md, MD | Neuromuscular Medicine | Wilmington, NC | $21,706 | $0 |
| Jeffrey Tamsing, M.d, M.D | Neurology | Parker, CO | $21,626 | $0 |
| Dr. Richard Nowak, M.d, M.D | Internal Medicine | New Haven, CT | $21,565 | $0 |
| Hanny Al-Samkari, Md, MD | Hematology & Oncology | Boston, MA | $21,470 | $0 |
| Sheetal Shroff, Md, MD | Student in an Organized Health Care Education/Training Program | Houston, TX | $21,373 | $0 |
| Rizwan Bajwa, Do, DO | Neurology | Hinsdale, IL | $20,325 | $0 |
| Paige Harris, Crnp, CRNP | Acute Care | Montgomery, AL | $19,734 | $0 |
| Dr. Tahseen Mozaffar, Md, MD | Neurology | Orange, CA | $19,262 | $0 |
Ad
Top Products
- VYVGART $13.5M
- VYVGART HYTRULO $12.1M
Associated Products (2)
- VYVGART $13.5M
- VYVGART HYTRULO $12.1M
Payment Categories
- Food & Beverage $1.1M
- Consulting $4.2M
- Travel & Lodging $768,052
- Research $23.2M
About ARGENX US, INC.
ARGENX US, INC. has made $32.2M in payments to 8,326 healthcare providers, recorded across 51,709 transactions in the CMS Open Payments database. In 2024, the company paid $14.0M. The top product by payment volume is VYVGART ($13.5M).
Payments were distributed across 150 medical specialties. The top specialty by payment amount is Neurology ($4.3M to 3,337 doctors).
Payment categories include: Food & Beverage ($1.1M), Consulting ($4.2M), Research ($23.2M), Travel & Lodging ($768,052).
ARGENX US, INC. is associated with 2 products in the CMS Open Payments database.